Outpatient use of cardiovascular drugs during pregnancy

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 3, 2008, Pages 240-247

  Andrade, Susan E ^a,b   Raebel, Marsha A ^b,c   Brown, Jeffrey ^b,d   Lane, Kimberly ^b,d   Livingston, James ^b,d   Boudreau, Denise ^b,e   Rolnick, Sharon J ^b,f   Roblin, Douglas ^b,c   Smith, David H ^b,c   Dal Pan, Gerald J ^g   Scott, Pamela E ^g   Platt, Richard ^b,d  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HMO Research Network Center for Education and Research in Therapeutics   (United States)

^c KAISER PERMANENTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e CENTER FOR HEALTH STUDIES   (United States)

^f HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^g CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Cardiovascular drugs; Fetal harm; Pregnancy

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC GLYCOSIDE; CARDIOVASCULAR AGENT; CLONIDINE; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; GEMFIBROZIL; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LABETALOL; LISINOPRIL; METHYLDOPA; METOPROLOL; NICOTINIC ACID; NIFEDIPINE; NITRIC ACID DERIVATIVE; PROPRANOLOL; TRIAMTERENE; UNINDEXED DRUG; VERAPAMIL;

ADOLESCENT; ADULT; ARTICLE; DELIVERY; DRUG SAFETY; DRUG USE; FEMALE; FETOTOXICITY; FETUS; GESTATIONAL AGE; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; OUTPATIENT; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERATOGENICITY; UNITED STATES;

ADOLESCENT; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR AGENTS; DATABASES, FACTUAL; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; OUTPATIENTS; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PREVALENCE; RETROSPECTIVE STUDIES; TERATOGENS; UNITED STATES;

EID: 40949105629     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1550     Document Type: Article

References (22)

1. National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2002; 183: S1-S22.
2. Klein LL, Galan HL. Cardiac disease in pregnancy. Obstet Gynecol Clin North Am 2004; 31: 429-459.
3. Gei AF, Hankins GD. Cardiac disease and pregnancy. Obstet Gynecol Clin North Am 2001; 28: 465-512.
4. Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 2006; 82: 23-28.
5. Tabacova S, Little R, Tsong Y, Vega A, Kimmel CA. Adverse pregnancy outcomes associated with maternal enalapril anti-hypertensive treatment. Pharmacoepidemiol Drug Saf 2003; 12: 633-646.
6. Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 2005; 73: 123-130.
7. Cooper WO, Hernandez-Diaz S, Arbogast PG. et al. Major congenital malformations after first-trimester exposure to ACE inhibitors. N Engl J Med 2006; 354: 2443-2451.
8. Edison RJ, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Genet A 2004; 131: 287-298.
9. Edison RJ, Muenke M. Central nervous system and limb anomalies in case reports of first-trimester statin exposure. N Engl J Med 2004; 350: 1579-1582. (Erratum in: N Engl J Med 2005; 352: 2759].
10. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191: 398-407.
11. Rubin JD, Ferencz C, Loffredo C. and the Baltimore-Washington Infant Study Group. Use of prescription and non-prescription drugs in pregnancy. J Clin Epidemiol 1993; 46: 581-589.
12. Ventura SJ, Abma JC, Mosher WD, Henshaw S. Estimated pregnancy rates for the United States, 1990-2000: an update. National vital statistics reports; vol 52 no 23. National Center for Health Statistics: Hyattsville, Maryland, 2004.
13. Andrade SE, Raebel MA, Morse AN, et al. Use of prescription medications with a potential for fetal harm among pregnancy women. Pharmacoepidemiol Drug Saf 2006; 15: 546-554.
14. Chan KA, Davis RL, Gunter MJ, et al. The HMO Research Network. In Pharmacoepidemiology (4th edn), Strom B (ed.). Wiley: Chichester, UK, 2005; 261-269.
15. Raebel MA, Ellis JL, Andrade SE. Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data. Pharmacoepidemiol Drug Saf 2005; 14: 829-836.
16. Roberts JM, Pearson G, Cutler J, Lindheimer M. NHLBI Working Group on Research on Hypertension During Pregnancy. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension 2003; 41: 437-445.
17. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183: S1-S22.
18. Solomon CG, Seely EW. Hypertension in pregnancy. Endocrinol Metab Clin North Am 2006; 35: 157-171.
19. Gregg AR. Hypertension in pregnancy. Obstet Gynecol Clin North Am 2004; 31: 223-241.
20. ACOG Committee on Practice Bulletins. ACOG practice bulletin. Chronic hypertension in pregnancy. Obstet Gynecol 2001; 98: 177-185.
21. Ables AZ, Romero AM, Chauhan SP. Use of calcium channel antagonists for preterm labor. Obstet Gynecol Clin North Am 2005; 32: 519-525.
22. Kastrup EK (ed.). Drug Fact and Comparisons, Wolters Kluwer Company: St. Louis, 2005.